New insights into the pathophysiology of multiple myeloma
Authors:
- Hannes KaufmannHKHannes Kaufmann
- Johannes DrachJDJohannes Drach
- 1 September 2003
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 4 (9) , 557-564
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variantsBlood, 2003
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Moving disease biology from the lab to the clinicCancer, 2003
- Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone diseaseCancer, 2003
- A molecular compendium of genes expressed in multiple myelomaBlood, 2002
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survivalBritish Journal of Haematology, 2002
- High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosisHuman Mutation, 2001
- p16 INK4a andp15INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significanceBlood, 2001
- MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMALBritish Journal of Haematology, 1996